GeneTx and Ultragenyx Announce Investigational New Drug
Investors & Media—Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Marin County's Ultragenyx Pharmaceutical reports Q2 loss of nearly $160 million
Press releases—Ultragenyx Pharmaceutical Inc.
Press releases—Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical, Inc. Aktie News
Ultragenyx Receives an Extended Approval for Evkeeza by the EC for 5 Years or Older Children with Homozygous Familial Hypercholesterolemia (HoFH)
Ultragenyx Fights for Cures Amid Rising R&D Costs - NAM
Ultragenyx Announces Proposed Public Offering of Common Stock | RARE Stock News
Events & presentations—Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc.
Press Release
Press releases—Ultragenyx Pharmaceutical Inc.
Ultragenyx Issues 2022 ESG Report, Continuing To Enhance Its Leadership on Corporate Responsibility
Foundation for Angelman Syndrome Therapeutics | FAST
Ultragenyx's Corporate Sustainability Journey—Ultragenyx
Press releases—Ultragenyx Pharmaceutical Inc.
Articles about Ultragenyx Pharmaceutical Inc.
